Leronlimab has proven by various means to be the best drug for HIV and S/C CD19. It has the same potential for many other indications. FDA EUA or approval for either HIV or S/C CD19 would be extremely detrimental to many BP's, most notably Gilead as it is prominent in both of these indications. This is the dilemma that the FDA has and to date they have chosen to protect BP at the expense of people who are or will soon be suffering from these afflictions. Something dramatic has to happen to change this. It is time to get the interim results and make them public.